BrukerBRKR
BRKR
About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
Employees: 9,707
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
67% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 5 (+2) [Q3]
29% more repeat investments, than reductions
Existing positions increased: 151 | Existing positions reduced: 117
7% more capital invested
Capital invested by funds: $7.44B [Q2] → $7.95B (+$506M) [Q3]
9% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 58
0% more funds holding
Funds holding: 362 [Q2] → 362 (+0) [Q3]
0.23% less ownership
Funds ownership: 77.18% [Q2] → 76.95% (-0.23%) [Q3]
14% less call options, than puts
Call options by funds: $2.35M | Put options by funds: $2.74M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
5%
upside
Avg. target
$71
24%
upside
High target
$80
41%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target | 41%upside $80 | Buy Maintained | 13 Dec 2024 |
UBS Dan Leonard 29% 1-year accuracy 2 / 7 met price target | 16%upside $66 | Neutral Assumed | 10 Dec 2024 |
Goldman Sachs Matthew Sykes 60% 1-year accuracy 25 / 42 met price target | 5%upside $60 | Neutral Upgraded | 5 Dec 2024 |
Citigroup Patrick Donnelly 47% 1-year accuracy 15 / 32 met price target | 32%upside $75 | Buy Maintained | 6 Nov 2024 |
TD Cowen Dan Brennan 41% 1-year accuracy 12 / 29 met price target | 23%upside $70 | Hold Maintained | 6 Nov 2024 |
Financial journalist opinion
Based on 7 articles about BRKR published over the past 30 days
Positive
Seeking Alpha
22 hours ago
Bruker Corporation Pivots To Capitalize Its Growing TAM
Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share. Recent acquisitions enhance BRKR's capabilities in high-growth markets like Life Sciences, Proteomics, and Spatial Biology, driving sustainable revenue growth and positioning the company for future demand. Despite current weaker EPS and operating margins, BRKR's strong R&D investment and successful integration of acquisitions are expected to boost profitability and growth by FY2025.
Positive
Zacks Investment Research
6 days ago
BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope
Bruker launches LUMOS II ILIM QCL-based IR microscope for pharma and life science research.
Neutral
Business Wire
1 week ago
Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution. The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both.
Neutral
Business Wire
1 week ago
Bruker Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 13th, 2025 at 3:45 PM Pacific Standard Time. A live audio webcast of the presentation will.
Neutral
Business Wire
3 weeks ago
Bruker Comments on Delaware District Court's Post-Trial Ruling in Case Involving GeoMx Digital Spatial Profiler Products
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today commented on the ruling of the U.S. District Court for the District of Delaware in the case involving GeoMx® Digital Spatial Profiler products sold by its NanoString business. Yesterday, the Court issued its ruling on the post-trial motions that followed the November 2023 jury verdict in the patent infringement case between NanoString and 10x Genomics. In its ruling, the District Court upheld the jury's damages award of.
Neutral
PRNewsWire
4 weeks ago
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products
PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies.
Positive
Zacks Investment Research
4 weeks ago
Bruker Adds Another 1.2 GHz NMR System in Switzerland, Stock Climbs
Bruker announces a 1.2 GHz NMR spectrometer at the Swiss High-field NMR facility.
Neutral
Business Wire
1 month ago
Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility
ZÜRICH--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities of several user groups, enabling advanced studies in structural biology and macromolecular analysis. The instrument, located at the University of Zürich, is the sec.
Positive
Zacks Investment Research
1 month ago
Why Is Bruker (BRKR) Up 0.9% Since Last Earnings Report?
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
1 month ago
Bruker Stock Might Rise From the Launch of Dimension Nexus AFM
BRKR launches the Dimension Nexus AFM at the 2024 MRS Fall Meeting & Exhibit, expanding its Dimension AFM product line.
Charts implemented using Lightweight Charts™